NewAmsterdam Pharma (NASDAQ:NAMS) Shares Up 2.6%

NewAmsterdam Pharma (NASDAQ:NAMS) shot up 2.6% on Tuesday . The stock traded as high as $20.26 and last traded at $20.26. 16,167 shares traded hands during mid-day trading, a decline of 93% from the average session volume of 232,322 shares. The stock had previously closed at $19.74.

Analyst Ratings Changes

Several brokerages have recently weighed in on NAMS. Guggenheim began coverage on NewAmsterdam Pharma in a report on Thursday, January 18th. They issued a “buy” rating and a $30.00 price target on the stock. Royal Bank of Canada increased their price target on NewAmsterdam Pharma from $25.00 to $31.00 and gave the stock an “outperform” rating in a report on Thursday, February 29th. Scotiabank assumed coverage on NewAmsterdam Pharma in a report on Thursday, March 14th. They set a “sector outperform” rating and a $35.00 price objective on the stock. Finally, Piper Sandler assumed coverage on NewAmsterdam Pharma in a report on Tuesday, January 16th. They set an “overweight” rating and a $37.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, NewAmsterdam Pharma currently has a consensus rating of “Buy” and a consensus target price of $33.25.

NewAmsterdam Pharma Trading Up 0.1 %

The firm has a fifty day simple moving average of $21.53 and a 200 day simple moving average of $15.09.

Insider Buying and Selling at NewAmsterdam Pharma

In related news, Director Louis G. Lange bought 5,000 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were acquired at an average price of $19.00 per share, with a total value of $95,000.00. Following the transaction, the director now owns 24,878 shares of the company’s stock, valued at $472,682. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, Director Louis G. Lange bought 5,000 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were acquired at an average price of $19.00 per share, with a total value of $95,000.00. Following the transaction, the director now owns 24,878 shares of the company’s stock, valued at $472,682. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director James N. Topper bought 8,429 shares of the company’s stock in a transaction on Tuesday, March 26th. The shares were bought at an average cost of $21.50 per share, for a total transaction of $181,223.50. Following the transaction, the director now directly owns 3,008,429 shares in the company, valued at approximately $64,681,223.50. The disclosure for this purchase can be found here. Insiders own 2.50% of the company’s stock.

Institutional Trading of NewAmsterdam Pharma

A number of institutional investors have recently made changes to their positions in the business. Wolverine Asset Management LLC acquired a new stake in shares of NewAmsterdam Pharma in the 3rd quarter worth $27,000. Geode Capital Management LLC boosted its position in shares of NewAmsterdam Pharma by 38.8% in the 2nd quarter. Geode Capital Management LLC now owns 25,768 shares of the company’s stock worth $306,000 after purchasing an additional 7,209 shares in the last quarter. Schonfeld Strategic Advisors LLC boosted its position in shares of NewAmsterdam Pharma by 12.9% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 64,700 shares of the company’s stock worth $598,000 after purchasing an additional 7,400 shares in the last quarter. Royal Bank of Canada boosted its position in shares of NewAmsterdam Pharma by 987.5% in the 4th quarter. Royal Bank of Canada now owns 10,875 shares of the company’s stock worth $121,000 after purchasing an additional 9,875 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of NewAmsterdam Pharma by 1,929.7% in the 1st quarter. JPMorgan Chase & Co. now owns 22,367 shares of the company’s stock worth $301,000 after purchasing an additional 21,265 shares in the last quarter. Institutional investors and hedge funds own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.